1	Serological surveillance reveals a high exposure to SARS-
2	CoV-2 and altered immune response among COVID-19
3	unvaccinated Cameroonian individuals
4	Arlette Flore Moguem Soubgui ^{1,2} , Wilfred Steve Ndeme Mboussi ^{1,2} , Loick Pradel Kojom
5	Foko ^{2,3*} , Elisée Libert Embolo Enyegue ⁴ , Martin Luther Koanga Mogtomo ^{1,2*}
6	¹ Department of Biochemistry, Faculty of Science, The University of Douala, Cameroon
7	² Centre de Recherche et d'Expertise en Biologie, Douala, Cameroon
8	³ Department of Animal Biology, Faculty of Science, The University of Douala, Cameroon
9	⁴ Center for Research on Health and Priority Diseases, Ministry of Scientific Research and
10	Innovation, Yaounde, Centre Region, Cameroon
11	Short title: SARS-CoV-2 seroprevalence and immune response in Cameroon
12	*Corresponding authors
13	koanga@yahoo.com (MLKM) and kojomloick@gmail.com (LPKF)
14	
15	ORCID Authors
16	Arlette Flore Moguem Soubgui (<u>https://orcid.org/0000-0001-8229-9533</u>)
17	Loick Pradel Kojom Foko (<u>https://orcid.org/0000-0002-4286-147X</u>)
18	Elisée Libert Embolo Enyegue (<u>https://orcid.org/0000-0002-5802-6858</u>)
19	Martin Luther Koanga Mogtomo (<u>https://orcid.org/0000-0003-4323-9428</u>)

20 Abstract

21 Background

- 22 Surveillance of COVID-19/SARS-CoV-2 dynamics is crucial to understanding natural history
- and providing insights into the population's exposure risk and specific susceptibilities. This
- study investigated the seroprevalence of SARS-CoV-2 antibodies, its predictors, and
- immunological status among unvaccinated patients in Cameroon.

26 Materials and Methods

- 27 A multicentre cross-sectional study was conducted between January and September 2022 in
- the town of Douala. Patients were consecutively recruited, and data of interest were
- 29 collected using a questionnaire. Blood samples were collected to determine Immunoglobin
- 30 titres (IgM and IgG) by ALFA, CD4+ cells by flow cytometry, and interferon gamma (IFN- γ)
- and interleukin-6 (IL-6) by ELISA.

32 **Results**

33 A total of 342 patients aged 41.5 ± 13.9 years were included. Most participants (75.8%) were 34 asymptomatic. The overall prevalence of IgM and IgG was 49.1% and 88.9%, respectively. Ageusia and anosmia have displayed the highest positive predictive values (90.9% and 35 36 82.4%) and specificity (98.9% and 98.3%). The predictors of IgM seropositivity were being aged 60 – 70 years (aOR = 0.54, p = 0.02) and ageusia (aOR = 9.31, p = 0.01), whereas those 37 of IgG seropositivity included health facility (aOR = 0.23, p = 0.02) and ageusia (aOR = 0.21, p38 39 = 0.04). CD4+, IFN- γ , and IL-6 were impaired in seropositive individuals, with a confounding role of socio-demographic factors or comorbidities. 40

41 **Conclusion**

- 42 Although the WHO declared the end of COVID-19 as a public health emergency, the findings
- 43 of this study indicate the need for continuous surveillance to adequately control the disease

44 in Cameroon.

45 Keywords

46 SARS-CoV-2; seroprevalence; predictors; immunological status; unvaccinated people;

47 Cameroon

48

49 Introduction

50 A large number of pathogens have emerged and re-emerged in the last two decades and 51 negatively impact the health, wellbeing, and economy of the world's populations. Several 52 factors, greatly due to anthropic activities and climate change, have been indexed as the main causes of the appearance and/or resurgence of several infectious diseases [1]. The 53 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a positive sense single-54 stranded ribonucleic acid virus, responsible for coronavirus disease 2019 (COVID-19) [2], is 55 the latest example of this catastrophic scenario of emerging pathogens. Since its initial 56 emergence in Wuhan, Hubei region, China, in December 2019, an estimated ~677 million 57 cases and ~6.9 million deaths were attributed to SARS-CoV-2 as of 10 March 2023 58 59 (https://coronavirus.jhu.edu/map.html).

Methods relying on molecular detection of the viral genome, i.e., retrotranscriptase
 quantitative polymerase chain reaction (RT-qPCR), are gold standards for diagnostic and

Page 4 of 38

62 surveillance purposes. In developed areas, RT-qPCR is highly operational at the national 63 level, but it is not the case in developing regions such as sub-Saharan Africa, where this technique is not affordable for most health facilities, especially those from remote and/or 64 hard-to-reach population areas. In addition, RT-qPCR-based estimates do not reflect the real 65 circulation and spread of SARS-CoV-2 in populations, as this technique can give false-66 67 negative results especially at initial testing (i.e., at the first healthcare encounter) [3], and is commonly recommended for individuals presenting COVID-19-like respiratory signs and 68 69 symptoms [4]. In this context, it is crucial to develop alternative methods to overcome these 70 main limitations of molecular techniques. Serological testing for SARS-CoV-2 infection has become an important pillar in surveillance 71 72 efforts. Seroprevalence studies quantify the number of individuals who have developed an 73 immune response, i.e. antibodies, against a pathogen. The studies rely of the detection of 74 immunoglobulins (e.g., IgG, IgM) produced followed infection with SARS-CoV-2. The production of these anti-SARS-CoV-2 antibodies corresponds to several phases of the natural 75 76 course of viral infection. IgM are produced early in the humoral immune response against 77 SARS-CoV-2 infection, and then they are switched to IgG, which has a higher affinity for viral 78 antigens than IgM [5,6]. Not only can the large scale implementation of highly sensitive and specific serological tests help to know the real picture of spread of SARS-CoV-2 by tracking 79 asymptomatic carriers of the virus who are missed by traditional surveillance systems, but 80 these can also evaluate the effectiveness of control measures [5]. 81

There is a lack of serological studies in African settings in the context of boosting efforts to continuous surveillance and control the disease. We therefore conducted a serological study to determine the prevalence and determinants of anti- SARS–CoV–2 antibodies among unvaccinated individuals living in the town of Douala, Cameroon. In addition, we evaluated
variations in markers of immune responses (interferon, lymphocytes, and interleukins).

87 Materials and Methods

88 Study design

89	This cross-sectional study was conducted between January, 1 st and September, 31 st , 2022 in
90	seven health facilities in the town of Douala, Littoral Region, Cameroon. The study sites
91	included Bangue district hospital, Boko health care centre, Bonassama district hospital, Cité
92	des Palmiers district hospital, Deido district hospital, New Bell district hospital, and Nylon
93	district hospital. Douala is the economic capital and most populated town of Cameroon.
94	Populations living in this town are highly diverse, with the predominance of three ethnic
95	groups (Duala, Bamileke, and Bassa) [7]. A questionnaire was administered to each
96	participant to collect sociodemographic, anthropometric, and clinical information, while
97	blood samples were collected to measure immune response parameters, respectively. A
98	summary of the main activities conducted during the study is summarized in Fig 1.
99	
100	Fig 1. Flow diagram of the study. COVID-19: Coronavirus disease 2019, Ig: Immunoglobulin,
101	CD: Cluster of differentiation, IFN-γ: Interferon gamma, IL-6: Interleukin 6

102

103 Eligibility criteria

We included all Cameroonian patients of both sexes, aged > 18 years old, settled in Douala,
and having signed an informed consent form. In contrast, we excluded from this study: i)

- 106 foreigners, ii) patients who were not willing to participate, iii) those who refused to sign an
- 107 informed consent form, iv) those admitted to intensive care units; and v) those for whom
- 108 blood collection was impossible.

Sample size calculation

- 110 Participants were recruited consecutively using random sampling to limit selection and
- information biases. The sample size was determined using Lorentz's formula $n = [Z^2 \times p \times (1 1)]$
- 112 p)]/d², where n = the required sample size, Z = statistics for the desired confidence interval (Z
- 113 = 1.96 for 95% confidence level), d = accepted margin of error (d = 5%), and p =
- seroprevalence of SARS-CoV-2 antibodies in Africa (19.5%) [8]. The required sample size for
- this study was estimated as n = 241 participants.

116 **Data collection**

- 117 About three millilitres of whole blood were collected from each patient by venepuncture in
- 118 properly labelled tubes. A structured pre-tested questionnaire was used to collect data of
- interest, which consisted of sociodemographic information (age, gender, educational level,
- 120 occupation, and marital status), anthropometric parameters (weight, height, body mass
- index), and clinical information (clinical signs and symptoms, COVID-19 vaccination uptake,
- and presence of comorbidities such as diabetes and hypertension).

Determination of immune response parameters

- 124 Venous blood samples were used to determine levels of CD4+, immunoglobulins M and G
- 125 (IgM and IgG), interferon gamma (IFN-γ) and interleukin 6 (IL-6). The blood level of CD4+ was
- 126 determined using a Sysmex XF-1600[™] Flow Cytometer (<u>https://www.sysmex-ap.com</u>). Blood

Page **7** of **38**

127	samples were centrifuged, and the resulting supernatant (serum) was used to determine
128	levels of immunoglobulins, IFN- γ , and IL-6. All serum samples were tested for anti-SARS-CoV
129	2 virus IgG and IgM antibodies using a VIDAS [®] SARS-COV-2 IgG/IgM kit (Reference 423833)
130	(www.biomerieux-usa.com) which is an automated assay based on the enzyme-linked
131	immunofluorescent assay (ALFA) technique. Samples were considered positive for both IgG
132	and IgM when the test values were greater than 1. IFN- γ and IL-6 were measured by
133	sandwich enzyme-linked immunosorbent assay (ELISA). Spectrophotometric measurements
134	of IFN- γ and IL-6 were done at wavelength 450 nm. All experiments were performed in
135	duplicate and in accordance with the manufacturer's instructions.

136 Ethical statements

- 137 An ethical authorization was issued by the institutional review board of the University of
- 138 Douala (N° 2945 CEI-UDo/12/2021/T), Littoral Health Regional Delegation (N° 0038/
- 139 AAR/MINSANTE/DRSPL/BCASS), and Douala Laquintinie Hospital (N°
- 140 08179/AR/MINSANTE/DHL) (S1 Fig). The study was explained to participants in the two
- 141 official languages they understood best (French or English), and their questions were
- answered. Patients were informed about the objectives, advantages, and risks of the study,
- and then asked to sign a written informed consent form before their enrolment. Participants
- 144 were informed that the study was strictly voluntary, and they were free to decline answering
- 145 any question or totally withdraw if they so wished at any time.

146 Statistical analysis

- 147 Data were presented as percentages with 95% confidence intervals (95%CI) for categorical
- 148 variables, and mean ± standard deviation (SD) or standard error (SE) for continuous

Page 8 of 38

149 variables. The percentages were compared using Fisher's exact and Pearson's independence 150 chi-square (χ^2) tests. Continuous variables were tested for normal distribution using the 151 Kolmogorov-Smirnov test to decide whether parametric and non-parametric statistical tests were suitable for comparative analyses (S2 Fig). Parametric tests including one-way analysis 152 of variance (ANOVA), post-hoc Duncan's test, unpaired samples Student t-test and Pearson 153 154 correlation were used for variables following a Gaussian distribution. The non-parametric versions of these tests (i.e., Kruskal-Wallis test, Mann-Whitney test and Spearman 155 156 correlation) were used for variables that failed to reach a Gaussian distribution. Univariate and multivariate logit models were used to identify determinants of SARS-CoV-2 antibodies. 157 The association between independent variables and SARS–CoV–2 antibodies was quantified 158 159 by crude and adjusted odds ratios (cOR and aOR), 95%CIs, and level of statistical significance. 160 The independent variables included in the logit model were health facility, gender, age, marital status, educational level, occupation, comorbidities, clinical signs and symptoms, 161 blood group, COVID-19 vaccination uptake, history of past COVID-19, and history of recent 162 163 infection). Based on the findings of the univariate analysis, variables that were significant in the univariate analysis were used to build the multivariate logistic model. A two-tailed p-164 165 value < 0.05 was considered statistically significant. No imputation was performed for 166 missing values. GraphPad version 5.03 for Windows (GraphPad PRISM, San Diego, Inc., 167 California, USA), SPSS version 16 for Windows (SPSS IBM, Inc., Chicago, Illinois, USA), and StatView version 5.0 for Windows (SAS Institute, Chicago, Illinois, USA) software were used 168 169 to perform statistical analyses. All analyses were performed as recommended in the SAMPL 170 Guidelines [9].

Results

173	SARS-CoV-2 antibody response by COVID-19 status
174	Unvaccinated patients accounted for 81.4% of the patients (Fig 2a). The serum titres of IgM
175	were significantly higher in unvaccinated patients compared to fully vaccinated patients (p =
176	0.03) (Fig 2b), but no significant difference was found for IgG (Fig 2c). Unvaccinated patients
177	were analysed in the next sections as per the study objectives.
178	
179	Fig 2. Proportion of unvaccinated patients (a), and serum levels of IgM (b) and IgG (c) by
180	COVID-19 vaccination status. The one-way analysis of variance (ANOVA) and Duncan's post-
181	hoc tests were used to make pairwise comparisons between groups. In Figures 2 b and 2c,
182	only statistically significant comparisons were showed on the graphs. *Statistically significant
183	at <i>p</i> -value < 0.05
184	
185	Characteristics of the unvaccinated participants
186	Of the 342 participants, females and elderly people accounted for 47.7% and 13.2%,
187	respectively. The mean age \pm SD of the study population was 41.5 \pm 13.9 years. Obesity was
188	the main comorbidity (24.6%) found in participants. The bulk of participants (75.8%) were
189	asymptomatic, even though a few individuals presented clinical symptoms represented
190	mainly by cough (12.1%), severe fatigue (10.9%), and headache (9%) (Table 1).
191	

193 Table 1. Details of the patients included in the study.

Variables	n (%)
Sociodemographic data (N = 342)	
Females, <i>n</i> (%)	163 (47.7%)
Age \geq 60 years, <i>n</i> (%)	45 (13.2%)
Mean age ± SD (years)	41.5 ± 13.9
Married, n (%)	179 (52.3%)
University level, n (%)	208 (60.8%)
Comorbidities (N = 342)	
Obesity, <i>n</i> (%)	84 (24.6%)
Hypertension, <i>n</i> (%)	37 (10.8%)
Diabetes, n (%)	21 (6.1%)
Asthma, <i>n</i> (%)	11 (3.2%)
Heart failure, n (%)	8 (2.3%)
Human immunodeficiency infection, n (%)	5 (1.5%)
Cancer, <i>n</i> (%)	2 (0.6%)
Stroke, <i>n</i> (%)	2 (0.6%)
Coronary heart disease, n (%)	1 (0.3%)
Renal impairment <i>, n</i> (%)	0 (0.0%)
Clinical signs/symptoms (N = 342)	
Asymptomatic, n (%)	258 (75.8%)
Cough <i>, n</i> (%)	49 (14.3%)
Severe fatigue, n (%)	40 (11.7%)

Headache, n (%)	35 (10.2%)
Fever, <i>n</i> (%)	32 (9.4%)
Respiratory difficulties, n (%)	27 (7.9%)
Sore throat, n (%)	27 (7.9%)
Running nose <i>, n</i> (%)	23 (6.7%)
Ageusia, n (%)	22 (6.4%)
Anosmia, n (%)	17 (4.9%)
Irritability/Confusion, n (%)	9 (2.6%)
Loss of appetite, n (%)	5 (1.5%)
Nausea, n (%)	4 (1.2%)
Diarrhoea, n (%)	4 (1.2%)
Vomiting, n (%)	2 (0.6%)

194

Overall prevalence of SARS–CoV–2 antibodies among COVID-19

196 **unvaccinated patients**

197 A high proportion of patients were positive for both anti-SARS-CoV-2 antibodies, with an

198 overall prevalence of 49.1% (*n* = 168, 95%Cl 43.9 – 54.4%) for IgM, and 88.9% (*n* = 304,

199 95%CI 85.1 – 91.8%) for IgG. By combining the two antibodies, the prevalence was 96.8% (*n*

200 = 331, 95%CI 94.3 – 98.2%). A statistically significant geographical variation in the prevalence

- of IgG, with the highest prevalence rate in patients from the Boko hospital (100%) and the
- lowest rate in patients from the Deido hospital (63.6%) (Fig 3 and S3 Table). No significant

203 difference was found between the prevalence of IgM (p = 0.51) or Ig G + IgM (p = 0.22) after 204 stratification by geographical area (Fig 3 and S3 Table).

205

Fig 3. Prevalence of SARS-CoV-2 antibodies by study sites. The map was generated using
AcgGIS v8.1 software (Esri, Redlands, CA, USA) and GraphPad version 5.03 for Windows
(GraphPad PRISM, San Diego, Inc., California, USA). The pie charts depict the prevalence of
patients positive for IgM (black section), IgG (pink section) and IgG + IgM (purple section).
*For Deido district hospital, the sample collection site was located in Bonamoussadi
neighbourhood. ** For Bangue district hospital, the sample collection site was located in

214 Seroprevalence profile by clinical status among COVID-19

215 unvaccinated patients

The prevalence of IgG and/or IgM by clinical symptoms is depicted in Figure 4. Overall, the 216 217 presence of IgM was more frequently seen among symptomatic patients. The trend was 218 inverted regarding IgG antibodies, but there was no statistically significant difference for the 219 concomitant presence of IgM + IgG. For instance, higher proportions of IgM+ patients were 220 found in those with fever (71.9% vs 46.8%, p = 0.0008), ageusia (90.9% vs 46.3%, p < 0.0001), 221 and anosmia (82.4% vs 47.4%, p = 0.005) (Fig 4 and S4 Table). Moreover, ageusia and 222 anosmia were the COVID-19 symptoms that displayed the highest positive predictive values 223 (90.9% and 82.4%) and specificity (98.9% and 98.3%) (S5 Table).

Page 13 of 38

225	Fig 4. Prevalence of SARS–CoV–2 antibodies by main clinical symptoms. Ig:
226	Immunoglobulin, n.s: Not significant, SARS–CoV–2: Severe acute respiratory syndrome
227	coronavirus 2. Each bar represents the proportion of patients seropositive with respect to
228	clinical symptoms. Only symptoms with occurrence > 15 were included in the analysis.
229	Pearson's independence chi-square and Fisher's exact tests were used to compare
230	percentages. *Statistically significant at * <i>p</i> -value < 0.05, ** <i>p</i> -value < 0.01, and *** <i>p</i> -value <
231	0.0001

232

233 Seroprevalence by demographical information and comorbidities

among COVID-19 unvaccinated patients

The variation of seroprevalence by demographical details and comorbidities is summarized in S6 Table. The prevalence of IgM was significantly higher in patients aged below 30 years (59.8%) and then decreased, with the lowest rates seen in patients 70 years (27.3%). The proportion of patients with IgG antibodies was higher in non-asthmatic patients as compared to their asthmatic counterparts (89.7% vs 63.6%, p = 0.02). No significant association was found between the presence of IgM and IgG antibodies, demographical characteristics, or comorbidities (S6 Table).

242 Determinants of SARS-CoV-2 antibody response among COVID-19

243 unvaccinated patients

Based on univariate logistic regression analysis, a total of four factors associated with the
presence of IgM antibodies were identified: age, marital status, frequent healthcare seeking,

246	and occupation. The risk of the presence of IgM was reduced by 63% in patients aged $60 - 70$
247	years (cOR = 0.37, 95%CI 0.16 – 0.84, $p = 0.01$) compared to those aged < 30 years. Similarly,
248	the risk of IgM was reduced by 75% (cOR = 0.25, 95%CI 0.07 – 0.94, <i>p</i> = 0.04) in divorced or
249	widowed patients, and by 51% (cOR = 0.49, 95%Cl 0.25 – 0.98, $p = 0.04$) in patients working
250	in the formal sector compared to singles and students, respectively. In contrast, the odds of
251	being positive for IgM were nearly two-fold higher in frequently seeking care individuals
252	(cOR = 1.71, 95%Cl 1.09 – 2.66, p = 0.01) (Table 2). Regarding IgG, two factors were identified
253	namely health facility and asthma. The risk of being positive for IgG was reduced in patients
254	from the Deido hospital (cOR = 0.16, 95%Cl 0.05 – 0.48, p = 0.002) compared to those
255	recruited at the Bangue hospital. Likewise, the odds of being positive for IgG were reduced in
256	asthmatic patients (cOR = 0.20, 95%Cl 0.06 – 0.72, <i>p</i> = 0.01).

257 Table 2. Univariate logistic regression between SARS-CoV-2 antibodies, demographical

258	information,	, clinical data and	l comorbidities among	COVID-19 unvacc	inated patients.
-----	--------------	---------------------	-----------------------	-----------------	------------------

		IgM		lgG	
Variables	Categories	cOR (95%CI)	p	cOR (95%CI)	p
Sociodemographic ch	aracteristics		1		1
Health facility	Bangue	1		1	
	Boko	0.73 (0.27 - 1.95)	0.53	0.71 (0.15 - 2.58)	0.97
	Bonassama	1.38 (0.73 - 2.60)	0.31	0.85 (0.29 - 2.51)	0.76
	Cité des Palmiers	1.10 (0.59 - 2.05)	0.76	0.73 (0.26 - 2.06)	0.55
	Deido	0.83 (0.33 - 2.09)	0.69	0.16 (0.05 - 0.48)	0.001*
	New-Bell	0.69 (0.33 - 1.46)	0.34	1.09 (0.28 - 4.26)	0.96
	Nylon	0.61 (0.26 - 1.41)	0.25	0.44 (0.13 - 1.42)	0.17

Age (years old)	< 30	1		1			
	[30 - 40[0.57 (0.31 - 1.04)	0.06	1.39 (0.56 - 3.47)	0.47		
	[40 - 50[0.59 (0.31 - 1.15)	0.06	1.83 (0.60 - 5.56)	0.28		
	[50 - 60[0.82 (0.41 - 1.66)	0.58	1.43 (0.46 - 4.37)	0.53		
	[60 - 70[0.37 (0.16 - 0.84)	0.01*	0.90 (0.29 - 2.82)	0.85		
	70+	0.25 (0.06 - 1.02)	0.05	0.70 (0.13 - 3.66)	0.66		
Gender	Females	1		1			
	Males	0.76 (0.49 - 1.16)	0.19	0.69 (0.35 - 1.37)	0.28		
Marital status	Single	1		1			
	Married	0.72 (0.46 - 1.11)	0.12	0.54 (0.26 - 1.11)	0.09		
	Divorced/Widow	0.25 (0.07 - 0.94)	0.04*	1.04 (0.12 - 8.73)	0.96		
Educational level	None/Primary	1		1			
	Secondary	0.93 (0.37 - 2.32)	0.88	0.83 (0.17 - 4.01)	0.82		
	University	0.98 (0.41 - 2.36)	0.97	0.77 (0.17 - 3.49)	0.73		
Occupation	Student	1		1			
	Formal sector	0.49 (0.25 - 0.98)	0.04*	0.63 (0.18 - 2.17)	0.45		
	Informal sector	0.59 (0.27 - 1.31)	0.19	0.53 (0.13 - 2.07)	0.35		
Clinical characteristics	Clinical characteristics						
Obesity	No	1		1			
	Yes	0.72 (0.44 - 1.18)	0.19	0.90 (0.42 - 1.94)	0.78		
Diabetes	No	1		1			
	Yes	0.49 (0.19 - 1.26)	0.14	0.73 (0.21 - 2.62)	0.63		
Hypertension	No	1		1			

	Yes	0.87 (0.44 - 1.72)	0.68	0.61 (0.23 - 1.56)	0.29
Heart failure	No	1		1	
	Yes	0.34 (0.07 - 1.69)	0.19	-	-
ні	No	1		1	
	Yes	0.69 (0.11 - 4.16)	0.68	0.49 (0.05 - 4.53)	0.53
Asthma	No	1		1	
	Yes	1.85 (0.53 - 6.43)	0.33	0.20 (0.06 - 0.72)	0.01*
History of COVID-19	No	1		1	
	Yes	0.79 (0.41 - 1.52)	0.48	5.61 (0.75 - 42.01)	0.09
Blood group	A	1		1	
	АВ	0.82 (0.28 - 2.45)	0.72	1.04 (0.12 - 9.28)	0.97
	В	0.63 (0.33 - 1.22)	0.17	1.07 (0.29 - 3.98)	0.91
	0	0.98 (0.58 - 1.63)	0.93	0.41 (0.16 - 1.04)	0.06
Frequently care seeking	No	1		1	
	Yes	1.71 (1.09 - 2.66)	0.01*	0.79 (0.39 - 1.59)	0.51

259 95%CI: Confidence interval at 95%, COVID-19: Coronavirus disease 2019, cOR: Crude odds ratio, aOR:

260 Adjusted odds ratio, HIV: Human immunodeficiency virus infection, Ig: Immunoglobulin, SARS–CoV–

261 2: Severe acute respiratory syndrome coronavirus 2

262 Univariate logistic regression analysis was performed to quantify the association between presence

263 of anti-SARS-CoV-2 antibodies (IgG and IgM), demographical information, clinical data and

264 comorbidities

265 *Statistically significant at *p*-value < 0.05

- 267 It was noted that the risk of being positive for IgM was increased but decreased for IgG in
- 268 symptomatic patients, especially for those with fever, pain, respiratory difficulties,
- 269 headache, severe fatigue, ageusia, or anosmia (Table 3). For instance, the IgM-related risk
- 270 was increased in patients with fever (cOR = 2.91, 95%Cl 1.30 6.49, *p* = 0.009), ageusia (cOR
- 271 = 11.62, 95%Cl 2.67 50.56, *p* = 0.0001), and anosmia (cOR = 5.18, 95%Cl 1.46 18.38, *p* =
- 0.01). Conversely, the risk of being positive for IgG was reduced by 85% (cOR = 0.15, 95%CI
- 273 0.07 0.35, *p* < 0.0001), 88% (cOR = 0.12, 95%CI 0.05 0.29, *p* < 0.0001), and 85% (cOR =
- 274 0.15, 95%CI 0.05 0.42, *p* = 0.0003) in patients with fever, ageusia, and anosmia,
- 275 respectively (Table 3).
- Table 3. Univariate logistic regression analysis between presence of anti-SARS-CoV-2
- 277 antibodies and clinical signs/symptoms among COVID-19 unvaccinated patients.

		IgM		lgG	
Variables	Categories	cOR (95%CI)	р	cOR (95%CI)	p
Cough	No	1		1	
	Yes	1.61 (0.87 - 2.97)	0.13	0.17 (0.08 - 0.35)	< 0.0001*
Fever	No	1		1	
	Yes	2.91 (1.30 - 6.49)	0.009*	0.15 (0.07 - 0.35)	< 0.0001*
Sore throat	No	1		1	
	Yes	1.85 (0.82 - 4.16)	0.14	0.51 (0.18 - 1.45)	0.21
Pain	No	1		1	
	Yes	2.86 (1.16 - 7.05)	0.02*	0.22 (0.09 - 0.56)	0.001*
Running nose	No	1		1	
	Yes	2.51 (1.01 - 6.27)	0.04*	0.25 (0.09 - 0.64)	0.004*

Respiratory difficulties	No	1		1	
	Yes	2.65 (1.13 - 6.22)	0.02*	0.31 (0.12 - 0.80)	0.01*
Diarrhea	No	1		1	
	Yes	1.04 (0.14 - 7.44)	0.97	0.37 (0.04 - 3.64)	0.39
Headache	No	1		1	
	Yes	3.36 (1.52 - 7.40)	0.002*	0.45 (0.18 - 1.11)	0.08
Severe fatigue	No	1		1	
	Yes	3.09 (1.49 - 6.42)	0.002*	0.19 (0.09 - 0.41)	< 0.0001*
Irritability/Confusion	No	1		1	
	Yes	2.11 (0.52 - 8.58)	0.29	0.23 (0.06 - 0.98)	0.04*
Ageusia	No	1		1	
	Yes	11.62 (2.67 - 50.56)	0.001*	0.12 (0.05 - 0.29)	< 0.0001*
Anosmia	No	1		1	
	Yes	5.18 (1.46 - 18.38)	0.01*	0.15 (0.05 - 0.42)	0.0003*
Loss of appetite	No	1		1	
	Yes	-	-	0.08 (0.01 - 0.48)	0.005*

278 95%CI: Confidence interval at 95%, cOR: Crude odds ratio, aOR: Adjusted odds ratio, Ig:

279 Immunoglobulin, SARS–CoV–2: Severe acute respiratory syndrome coronavirus 2

280 Univariate logistic regression analysis was performed to quantify the association between presence

281 of anti-SARS-CoV-2 antibodies (IgG and IgM) and clinical signs/symptoms

282 *Statistically significant at *p*-value < 0.05

283

285 **Predictors of anti-SARS-CoV-2 antibody response among**

286 unvaccinated patients

287	The predictors of the presence of IgM antibodies included age and ageusia, while health
288	facilities and ageusia were predictors of the presence of IgG antibodies (Table 4 and S7
289	Table). The risk of being positive for IgM was reduced by 46% in patients aged 60 – 70 years
290	(aOR = 0.54, 95%Cl 0.18 – 0.87, p = 0.02). In contrast, the odds of IgM seropositivity were
291	increased in patients diagnosed with ageusia (aOR = 9.31 , 95% Cl $1.49 - 58.08$, $p = 0.01$).

292 Table 4. Predictors of the presence of anti-SARS-CoV-2 antibodies among COVID-19

293 unvaccinated patients.

	lgM lgG		lgG	
Predictors	aOR (95%CI)	р	aOR (95%CI)	р
Health facility, Deido	-	-	0.23 (0.06 - 0.83)	0.02*
Aged 60 - 70 years	0.54 (0.18 - 0.87)	0.02*	-	-
Ageusia	9.31 (1.49 - 58.08)	0.01*	0.21 (0.04 - 0.98)	0.04*

294 95%CI: Confidence interval at 95%, COVID-19: Coronavirus disease 2019, aOR: Adjusted odds ratio,

aOR: Adjusted odds ratio, lg: Immunoglobulin

296 Multivariate logistic regression analysis was performed to identify the predictors of the presence of

297 anti-SARS-CoV-2 antibodies (IgG and IgM)

298 *Statistically significant at *p*-value < 0.05

299

301 Variation of the SARS–CoV–2 immune response among

302 unvaccinated patients

The variations in mean levels of CD4+ cells, IFN- γ , and IL-6 by seropositivity status are depicted in Figure 5. No significant variation was noted for CD4+ between IgM+ patients and IgM- patients (p = 0.11). In contrast, increased levels have been observed in IFN- γ (p = 0.01) and IL-6 (p = 0.04) in IgM+ patients compared to their IgM- counterparts. Regarding IgG status, the levels of CD4+ cells were significantly higher in IgG+ patients (p = 0.0048), but an inverted relation was found for IL-6 (p = 0.0001). The levels of IFN- γ were similar between IgG+ patients and IgG- patients (p = 0.87) (Fig 5).

The impact of patients' characteristics (i.e., sociodemographic, anthropometric, and clinical 310 311 information) on the relation between seropositivity status, and CD4+ cells, IFN-γ, or IL-6 was 312 analysed (Fig 6). For instance, we compared the mean values of CD4+ cells, IFN-y, and IL-6 of 313 IgM+ females with those of IgM- females, and the same comparisons were done for males. 314 Overall, the relationship between CD4+ cells and IgM or IgG status was not influenced by patients' characteristics, with the exception of symptomatology and diabetes. The mean 315 316 levels of CD4+ were significantly reduced in IgM+ symptomatic patients compared to IgM-317 symptomatic patients (p = 0.01), but the difference was no longer significant between IgM+ 318 asymptomatic patients and IgM- asymptomatic patients (p = 0.16). Likewise, the same 319 pattern was noted upon stratification of the patients by diabetic status, with a significant 320 difference in CD4+ cells in diabetic patients (p = 0.01) but no longer in non-diabetic patients 321 (p = 0.20). CD4+ cells were significantly higher in IgM+ non-diabetic compared to IgM+ non-322 diabetic (p = 0.005), but not in diabetic patients (p = 0.56). The association between seropositivity status and IFN- γ or IL-6 was also modified by the patient's details (Fig 6). 323

Page **21** of **38**

324	Fig 5. Overall variation of CD4+ (a, d), IFN- γ (b, e) and IL-6 (c, f) with respect to presence of
325	anti-SARS-CoV-2 IgM and IgG antibodies. Ig: Immunoglobulin, IL-6: Interleukin 6, IFN-γ:
326	Interferon gamma, CD: Cluster of differentiation. The parametric unpaired sample Student's
327	t-test, and non-parametric Mann-Whitney test ere used to compare the groups. *Statistically
328	significant at <i>p</i> -value < 0.05
329	
330	Fig 6. Variation of CD4+, INF- γ and IL-6 by seropositivity status, demographic, clinical, and
331	comorbidity information. Ig: Immunoglobulin, SARS–CoV–2: Severe acute respiratory
332	syndrome coronavirus 2, IL-6: Interleukin 6, IFN-γ: Interferon gamma, CD: Cluster of
333	differentiation. The number of participants in each group are presented in round brackets.
334	The non-parametric unpaired sample Student's t-test was used to compare the groups.
335	*Statistically significant at <i>p</i> -value < 0.05
336	

337 **Discussion**

338 The epidemiological situation of SARS–CoV–2 infection is still elusive in Cameroon, and this is 339 mainly due to a lack of testing campaigns in community. Molecular methods are the gold 340 standard for SARS-CoV-2 testing in populations. In developing countries, their 341 implementation at a large scale is strongly hindered by the high cost of these methods, 342 which are limited to a few research institutes and health facilities for research and smallscale diagnosis purposes. Antibody-based assays constitute an interesting alternative to 343 molecular methods, especially for the rapid determination of the circulation of SARS–CoV–2. 344 345 This study aimed at determining the seroprevalence and determinants of SARS–CoV–2 antibodies among patients attending major health facilities for the management of COVID-346 19 in Douala, Cameroon. 347

Page 22 of 38

348 The overall seroprevalence of SARS-CoV-2 was 96.9%, which is consistent with those 349 reported in other settings such as Chile (97.3%) [10]. In contrast, lower seroprevalence 350 values were recently reported in Portugal (2.7 – 3.9%), Mozambique (3%), Bosnia and Herzegovina (3.77%), Japan (3.9%), Denmark (5.3%), Chile (7.2%), Spain (9.6 - 21.9%), Italia 351 352 (11%), Sweden (11.8%), Iran (14%), Pakistan (16%), Iran (17.1%), Iraq (23.72%), Poland 353 (42.7%), USA (5.6 – 57.7%), and Lebanon (58.9%) [4,11,20–27,12–19]. Differences in study period, SARS–CoV–2 variants, age groups, and COVID–19 vaccine coverage could explain 354 discrepancies between seroprevalence estimates. Also, we found higher seroprevalence 355 356 against IgM compared to IgG. This is not in line with reports from Iraq, where authors found 357 higher seroprevalence against IgG [4]. We noted that a high proportion of seropositive 358 patients were asymptomatic, and this could indicate that patients could control the SARS-CoV-2 infection. A study found cross-reactive antibodies to SARS-CoV-2 were in circulation 359 among HIV patients before the COVID-19 pandemics [28], thereby suggesting the presence 360 of pre-existing anti-SARS-CoV-2- immunity that could contribute to attenuating disease 361 362 severity.

363 The presence of IgM antibodies to SARS-CoV-2 is a good proxy for recent infection, as they 364 are produced early in the antiviral humoral immune response. Nearly half of unvaccinated patients were IgM positive, thereby suggesting a high circulation of SARS-CoV-2 among the 365 patients, and a need for adequate control measures, especially for those manifesting COVID-366 367 19-related symptoms. This is the first seroprevalence study to report SARS-CoV-2 risk in adults in Douala, the main populous and heterogeneous town of Cameroon. Before our 368 study, IgM seroprevalence estimates were available from studies conducted among health 369 370 care workers and the general population in the town of Yaoundé [29–31].

Page 23 of 38

371 The prevalence of IgG was 88.9% in this study. Such a high prevalence estimate was also 372 reported in Cameroon by Ndongo Ateba et al. in Yaounde (18.6% to 51.3%) [32], Mansuy et 373 al. in pregnant women from Yaoundé (77%) [33], Njuwa Fai et al. in a community-based 374 study from Yaoundé (24%) [31], Deutou Wondeu et al. among university staff and students 375 (71.3%) in Bandjoun, a kingdom in the West Region of Cameroon [34], Sandie et al. among 376 blood donors from Douala and Yaoundé (66.3% to 98.4%) [35], and Diallo et al. among unvaccinated individuals (74.8%) after the Omicron wave [36]. Lower values were reported 377 378 among dental teams in Germany (5.2%) [37] and young adults in Sweden (22.4%) [25]. The 379 chances of detecting anti-SARS-CoV-2 IgG were decreased by 77% in patients attending the 380 Deido district hospital compared to those attending the Bangue district hospital. This finding 381 could be explained by geographical differences in the risk of infection, which have also been reported in previous studies [11]. 382

383 Patients aged 60 – 70 years were less at risk of IgM seropositivity, which is consistent with 384 earlier studies [14,19,22,36,38,39]. In Bosnia and Herzegovina, Prguda-Mujic and colleagues 385 reported a reduced risk of positive anti-SARS CoV-2 Ig levels in patients aged over 50 years 386 old [19]. Other studies reported a reduced risk of SARS-CoV-2 positivity in younger 387 individuals [21,40]. This could be due to the fact that elderly individuals are more aware of risks of COVID-19, and thus preventive methods could be more effectively implemented in 388 them [41]. This fact could also explain the reduced risk of anti-SARS CoV-2 IgG levels among 389 390 asthmatic patients found in the present study.

In this study, clinical symptoms were significantly associated with a higher risk of IgM
 seropositivity, especially anosmia and ageusia. In addition, ageusia was the strongest
 predictor of IgM seropositivity among the patients. Several studies across COVID-19 burden

Page 24 of 38

394 varying settings also reported the clinical utility of COVID-19 evocating clinical symptoms, or 395 more specifically, fever, anosmia, and ageusia [20,22,23,25,26,40,42]. Ferreira et al. recently 396 reported that anosmia/dysgeusia was the most clinically discriminant symptoms in Portuguese municipal workers, with a PPV and specificity of 52.2% and 99.3%, respectively. 397 398 Likewise, we found high estimates for anosmia (PPV = 82.4%, Sp = 98.3%) and for ageusia 399 (PPV = 90.9%, Sp = 98.9%) in this study. The pathophysiological mechanism of anosmia and ageusia in COVID-19 is not yet fully understood, but studies have outlined that SARS-CoV-2 400 401 could elicit these olfactory and gustatory dysregulations either directly by infecting central 402 nervous system and gustatory/olfactory epithelium cells, or indirectly through the production of cytokines such as tumour necrosis factor that may provoke the apoptosis of 403 404 nervous cells [43,44].

405 In line with previous studies, the levels of IFN-y and CD4+ cells were decreased in 406 seropositive patients. Several studies outlined a delayed, decreased, or inhibited IFN-y-407 mediated immune response in SARS-CoV-2 and other related coronaviruses (e.g., SARS-408 CoV-1). This dysregulation of the IFN- γ -mediated immune response is positively correlated 409 with the severity of COVID–19 [45,46]. The pathophysiological mechanism through which 410 SARS–CoV–2 provokes a dysregulation of the IFN-y-mediated immune response included a production of antagonists that act by downregulating signalling pathways and/or inhibiting 411 transcription factors [45,46]. Regarding CD4+ lymphocytes, they play a crucial role in the 412 413 immune response against SARS–CoV–2 [47–49]. COVID–19 patients generally present a 414 lymphopenia. Some authors suggested that the surveillance of lymphocyte subsets could be helpful for improved diagnosis and treatment of COVID-19 patients [50]. To be noted, the 415 416 association between antibody seropositivity and CD4+, IFN-y or IL-6 was modulated by patients' characteristics. Such modulating impact have been previously reported for immune 417

418	response immune in India [51], and haematological biomarkers of COVID-19 in Cameroon
419	and India [52,53]. This is not surprising as these characteristics are well known to be
420	predictors of SARS-CoV-2 infection, severity, or deaths [54–56].
421	The findings from the present study should be interpreted in light of its limitations. First, the
422	study was conducted in seven health facilities in the town of Douala, thereby limiting its
423	generalisability at national level. Second, the study did not capture all environmental,
424	behavioural, and socio-demographic characteristics of patients (e.g., size of household,
425	socio-economic status) that could have impacted the risk of SARS-CoV-2 seropositivity
426	[21,23,42,57–59]. Third, the small number of patients with comorbidities such as heart
427	failure limited stratification analyses to identify possible confounding variables. Finally, the
428	antigens in the ELISA kits used were designed to target the original SARS-CoV-2 lineage that
429	emerged in China. Several variants of the virus, such as the Omicron or delta lineages, have
430	been reported in Cameroon during pandemic waves [60–62], and thus, it is likely that a few
431	infection cases were missed as these antigens may not optimally detect antibodies against
432	SARS-CoV-2 variants and that the seroprevalence is underestimated.

433 **Conclusions**

In this study, we aimed at determining seroprevalence, determinants of SARS-CoV-2
infection, and immunological alterations among unvaccinated patients living in Douala,
Cameroon. The findings indicate a high circulation of the virus among participants, with
several predictors of seropositivity including advanced age, health facility, and ageusia. In
general, immune response effectors (CD4+, IFN-γ, and IL-6) analysed in the study were
altered in seropositive individuals, with a confounding role of socio-demographic factors or
comorbidities. Although the WHO recently declared the end of COVID-19 as a global health

441 emergency, the findings of the present study indicate the need for continuous surveillance442 to adequately control the disease in Cameroon.

443 **Abbreviations**

- 444 95%CI: Confidence interval at 95%, ALFA: Enzyme-linked immunofluorescent assay, ANOVA:
- 445 Analysis of variance, aOR: Adjusted odds ratio, cOR: Crude odds ratio, aRR: Adjusted risk
- ratio, BMI: Body mass index, CD: Cluster of differentiation, cRR: Crude risk ratio, COVID–19:
- 447 Coronavirus disease 2019, df: Degree of freedom, ELISA: Enzyme-linked immunosorbent
- 448 assay, IFN: Interferon, Ig: Immunoglobulin, HIV: Human immunodeficiency virus, PPV:
- 449 Positive predictive value, ROC: Receiver operating curve, RT-qPCR: Retrotranscriptase
- 450 quantitative polymerase chain reaction, SARS–CoV–2: Severe acute respiratory syndrome
- 451 coronavirus 2, SD: Standard deviation, SE: Standard error, Sp: Specificity

452 Acknowledgments

453 The authors are grateful to patients having accepted to participate in the study. We also

acknowledge support and technical assistance of managing authorities, medical doctors and

- staff of health facilities. We also acknowledge the assistance of Mr. Stephane Koum
- 456 (Department of Earth Sciences, The University of Douala, Cameroon) for generating maps.

457 Author Contributions

458 **Conceptualization**: Arlette Flore Moguem Soubgui, Martin Luther Koanga Mogtomo.

459 Data curation: Arlette Flore Moguem Soubgui, Wilfred Steve Ndeme Mboussi, Loick Pradel

460 Kojom Foko, Elisee Libert Embolo Enyegue.

- 461 Formal analysis: Arlette Flore Moguem Soubgui, Loick Pradel Kojom Foko, Martin Luther
- 462 Koanga Mogtomo.
- 463 Investigation: Arlette Flore Moguem Soubgui, Wilfred Steve Ndeme Mboussi, Elisee Libert
- 464 Embolo Enyegue, Martin Luther Koanga Mogtomo.
- 465 **Methodology**: Arlette Flore Moguem Soubgui, Wilfred Steve Ndeme Mboussi, Loick Pradel
- 466 Kojom Foko, Elisee Libert Embolo Enyegue, Martin Luther Koanga Mogtomo.
- 467 **Resources**: Arlette Flore Moguem Soubgui, Martin Luther Koanga Mogtomo.
- 468 **Project administration**: Martin Luther Koanga Mogtomo.
- 469 **Software**: Loick Pradel Kojom Foko.
- 470 **Supervision**: Martin Luther Koanga Mogtomo.
- 471 **Validation**: Loick Pradel Kojom Foko, Martin Luther Koanga Mogtomo.
- 472 Writing original draft: Arlette Flore Moguem Soubgui, Loick Pradel Kojom Foko.
- 473 Writing review & editing: Loick Pradel Kojom Foko, Martin Luther Koanga Mogtomo.

474 Data availability statement

- 475 All data are within the manuscript and supporting files, and relevant data underlying the
- 476 results presented in the study has been filed in the Dryad repository and available from
- 477 <u>https://doi.org/10.5061/dryad.1vhhmgr00</u>.

478 Funding

479 The author(s) received no specific funding for this work.

480 **Competing interests**

481 The authors have declared that no competing interests exist.

482 **References**

- 483 1. Kojom LP, Singh V. A review on emerging infectious diseases prioritized under the
- 484 2018 WHO Research and Development Blueprint: Lessons from the Indian context.
- 485 Vector Borne Zoonotic Dis. 2021;21(3):149–59.
- 486 2. Gautret P, Million M, Jarrot PA, Camoin-Jau L, Colson P, Fenollar F, et al. Natural
- 487 history of COVID-19 and therapeutic options. Expert Rev Clin Immunol.
- 488 2020;16(12):1159–84. Available from:
- 489 https://doi.org/10.1080/1744666X.2021.1847640
- 490 3. Arevalo-Rodriguez I, Buitrago-Garcia D, Simancas-Racines D, Zambrano-Achig P,
- 491 Campo R Del, Ciapponi A, et al. False-negative results of initial RT-PCR assays for
- 492 COVID-19: A systematic review. PLoS One. 2020;15(12):e0242958.
- 493 4. Saeed AY, Assafi MS, Othman HE, Shukri HM. Prevalence of SARS -CoV-2 IgG/IgM
- 494 antibodies among patients in Zakho City, Kurdistan, Iraq. J Infect Dev Ctries.
- 495 2022;16(7):1126–30.
- 496 5. Mallano A, Ascione A, Flego M. Antibody response against SARS-CoV-2 infection:
- 497 Implications for diagnosis, treatment and vaccine development. Int Rev Immunol.
- 498 2022;41(4):393–413. Available from:
- 499 https://doi.org/10.1080/08830185.2021.1929205
- 500 6. Zhou W, Xu X, Chang Z, Wang H, Zhong X, Tong X, et al. The dynamic changes of serum

501	IgM and IgG against SARS-Co	V-2 in patients with COVID-19. J Med Virol.
-----	-----------------------------	---

502 2021;93(2):924–33.

- 503 7. Kojom Foko LP, Nolla NP, Nyabeyeu Nyabeyeu H, Lehman LG. Prevalence, patterns,
- and determinants of malaria and malnutrition in Douala , Cameroon : A cross-

sectional community-based study. Biomed Res Int. 2021;2021:5553344.

8. Bobrovitz N, Arora RK, Cao C, Boucher E, Liu M, Donnici C, et al. Global seroprevalence

507 of SARS-CoV-2 antibodies: A systematic review and metaanalysis. PLoS One.

- 508 2021;16:e0252617. Available from: http://dx.doi.org/10.1371/journal.pone.0252617
- 509 9. Lang TA, Altman DG. Basic statistical reporting for articles published in Biomedical
- 510 Journals: The "Statistical analyses and methods in the published literature" or the

511 SAMPL guidelines. Int J Nurs Stud. 2015;52(1):5–9. Available from:

- 512 http://dx.doi.org/10.1016/j.ijnurstu.2014.09.006
- 513 10. Aguilera X, González C, Apablaza M, Rubilar P, Icaza G, Ramírez-Santana M, et al.
- 514 Immunization and SARS-CoV-2 antibody seroprevalence in a country with high

515 vaccination coverage: Lessons from Chile. Vaccines. 2022;10(7):1002.

- 516 11. Poustchi H, Darvishian M, Mohammadi Z, Shayanrad A, Delavari A, Bahadorimonfared
- 517 A, et al. SARS-CoV-2 antibody seroprevalence in the general population and high-risk
- occupational groups across 18 cities in Iran: a population-based cross-sectional study
 Hossein. Lancet Infect Dis. 2021;21:473–81.
- 520 12. Arnaldo P, Mabunda N, Young PW, Tran T, Sitoe N, Chelene I, et al. Prevalence of
- 521 SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic
- 522 study in three cities, July-August 2020. Clin Infect Dis. 2022;75(S2):S285–93.

- 13. Bahlawan O, Badra R, Semaan H, Fayad N, Kamel MN, El Taweel AN, et al. Prevalence
- and determinants of SARS-CoV-2 neutralizing antibodies in Lebanon. Arch Virol.
- 525 2022;167(7):1509–19. Available from: https://doi.org/10.1007/s00705-022-05470-2
- 526 14. Clarke KEN, Jones JM, Deng Y, Nycz E, Lee A, Iachan R, et al. Seroprevalence of
- 527 infection-induced SARS-CoV-2 antibodies-United States, September 2021-February
- 528 2022. Morb Mortal Wkly Rep. 2022;71(17):606–8. Available from:
- 529 https://www.medrxiv.org/content/10.1101/2022.04.18.22271936v1?rss
- 530 15. Goss CW, Maricque BB, Anwuri V V, Cohen RE, Donaldson K, Johnson KJ, et al. SARS-
- 531 CoV-2 active infection prevalence and seroprevalence in the adult population of St.
- 532 Louis County. Ann Epidemiol. 2022;71:31–7.
- 533 16. Johannesen CK, Martin GS, Lendorf ME, Garred P, Fyfe A, Paton RS, et al. Prevalence
- and duration of anti-SARS-CoV-2 antibodies in healthcare workers. Dan Med J.
- 535 2022;69(5):A11210843.
- 536 17. Moreno S, Miró Q, Soler A, Gallego M, Homs M, Garcia MJ. Prevalence of SARS-CoV-2
- 537 antibodies and risk factors in the pandemic epicentre of Catalonia. Sci Rep.
- 538 2022;12(1):9169. Available from: https://doi.org/10.1038/s41598-022-13290-2
- 18. Mori Y, Tanaka M, Kozai H, Hotta K, Aoyama Y, Shigeno Y, et al. Prevalence of SARS-
- 540 CoV-2 antibodies among university athletic club members: A cross-sectional survey.
 541 Drug Discov Ther. 2022;16(4):185–90.
- 542 19. Prguda-Mujic J, Hasanic O, Besic L, Asic A, Halilovic S, Cesic AK, et al. Antibody
- 543 seroprevalence against SARS-CoV-2 within the Canton of Sarajevo, Bosnia and
- 544 Herzegovina-One year later. PLoS One. 2022;17(3):e0265431. Available from:

Page **31** of **38**

545 http://dx.doi.org/10.1371/journal.pone.0265431

Vena A, Berruti M, Adessi A, Blumetti P, Brignole M, Colognato R, et al. Prevalence of
antibodies to SARS-CoV-2 in Italian adults and associated risk factors. J Clin Med.
2020;9(9):2780.

549 21. Żółtowska B, Barańska I, Jachowicz E, Sydor W, Maziarz B, Mydel K, et al. The

550 seroprevalence of SARS-CoV-2 antibodies among healthcare workers in university

551 hospital in Krakow before the era of vaccination. Int J Environ Res Public Health.

552 2022;19(7):4044.

Zuñiga M, Lagomarcino AJ, Muñoz S, Peña A, Andrea M, O'Ryan ML. A cross sectional
 study found differential risks for COVID-19 seropositivity amongst health care
 professionals in Chile. J Clin Epidemiol. 2022;144:72–83.

556 23. Javed W, Abidi SHB, Baqar J Bin. Seroprevalence and characteristics of Coronavirus

557 Disease (COVID-19) in workers with non-specific disease symptoms. BMC Infect Dis.

558 2022;22:481. Available from: https://doi.org/10.1186/s12879-022-07461-9

559 24. Arabkhazaeli A, Maghsudlu M, Mohammadi S, Eshghi P. Positive anti-SARS-CoV-2

rapid serological test results among asymptomatic blood donors. Transfus Clin Biol.
2022;29(1):24–30.

Bjorkander S, Du Ll, Zuo F, Ekstrom S, Wang Y, Wan H, et al. SARS-CoV-2–specific Band T-cell immunity in a population-based study of young Swedish adults. J Allergy
Clin Immunol. 2022;149(1):65–75.

565 26. Ferreira NB, Pereira H, Pereira AM, Azevedo LF, Santos M, Maranhão P, et al.

566 Seroprevalence of SARS-CoV-2 and assessement of epidemiological determinants in

567		Portugese municipal workers. Int J Occup Med Environ Health. 2022;35(3):297–307.
568	27.	Martínez CA, Pastor JCS, Sánchez IMM, Giménez AN, de Antón MG, Chacón PA.
569		Prevalence of SARS-CoV-2 infection during the first wave of the pandemic among
570		health and non-health personnel of the General Hospital of Segovia, Castilla y León.
571		Rev Esp Quimioter. 2022;35(2):157–64.
572	28.	Aissatou A, Fokam J, Semengue ENJ, Takou D, Ka'e AC, Ambe CC, et al. Pre-existing
573		immunity to SARS-CoV-2 before the COVID-19 pandemic era in Cameroon: A
574		comparative analysis according to HIV-status. Front Immunol. 2023;14:1155855.
575	29.	Nwosu K, Fokam J, Wanda F, Mama L, Orel E, Ray N, et al. SARS-CoV-2 antibody
576		seroprevalence and associated risk factors in an urban district in Cameroon. Nat
577		Commun. 2021;12:5851.
578	30.	Nguwoh PS, Mboringong AB, Fokam J, Ngounouh Taheu C, Halilou I, Djieudeu Nouwe
579		SH, et al. Seroprevalence of SARS-CoV-2 (COVID-19) among health care workers in
580		three health facilities of Yaounde, Center Region of Cameroon. Eur J Med Health Sci.
581		2021;3(6):89–94.
582	31.	Fai KN, Corine TM, Bebell LM, Mboringong AB, Nguimbis EBPT, Nsaibirni R, et al.
583		Serologic response to SARS-CoV-2 in an African population. Sci African.
584		2021;12:e00802. Available from: https://doi.org/10.1016/j.sciaf.2021.e00802
585	32.	Ndongo Ateba F, Guichet E, Mimbé ED, Ndié J, Pelloquin R, Varloteaux M, et al. Rapid
586		increase of community SARS-CoV-2 seroprevalence during second wave of COVID-19,
587		Yaoundé, Cameroon. Emerg Infect Dis. 2022;28(6):1233–6.
588	33.	Mansuy JM, Kenfack M, Burel S, Bidzogo Lebobo M, Ekae C, Berry A, et al. High SARS-

- 589 CoV-2 IgG seroprevalence among pregnant Cameroun women 14 months after the 590 beginning of the pandemic. Public Health. 2022;S0033-3506(22)00260-8.
- 591 34. Deutou Wondeu AL, Talom BM, Linardos G, Ngoumo BT, Bello A, Soufo AMN, et al.
- 592 The COVID-19 wave was already here: High seroprevalence of SARS-CoV-2 antibodies
- among staff and students in a Cameroon University. J Public Health Africa.
- 594 2023;14(1):2242.
- 595 35. Sandie AB, Ngo Sack F, Medi Sike CI, Mendimi Nkodo J, Ngegni H, Ateba Mimfoumou
- 596 HG, et al. Spread of SARS-CoV-2 infection in adult populations in Cameroon: A
- 597 repeated cross-sectional study among blood donors in the cities of Yaoundé and
- 598 Douala. J Epidemiol Glob Health. 2023;13(2):266–78. Available from:
- 599 https://doi.org/10.1007/s44197-023-00102-7
- 600 36. Diallo MSK, Amougou-Atsama M, Ayouba A, Kpamou C, Mimbe Taze ED, Thaurignac G,
- 601 et al. Large diffusion of severe acute respiratory syndrome coronavirus 2 after the
- successive epidemiological waves, including Omicron, in Guinea and Cameroon:
- 603 Implications for Vaccine Strategies. Open Forum Infect Dis. 2023;10(5):ofad216.
- 604 Available from: https://doi.org/10.1093/ofid/ofad216
- 605 37. Mksoud M, Ittermann T, Holtfreter B, Söhnel A, Söhnel C, Welk A, et al. Prevalence of
- 606 SARS-CoV-2 IgG antibodies among dental teams in Germany. Clin Oral Investig
- 607 [Internet]. 2022;26(5):3965–74. Available from: https://doi.org/10.1007/s00784-021-
- 608 04363-z
- 609 38. Chang L, Hou W, Zhao L, Zhang Y, Wang Y, Wu L, et al. The prevalence of antibodies to
 610 SARS-CoV-2 among blood donors in China. Nat Commun. 2021;12:1383.

611	39.	Fogh K, Eriksen ARR, Hasselbalch RB, Kristensen ES, Bundgaard H, Nielsen SD, et al.
612		Seroprevalence of SARS-CoV-2 antibodies in social housing areas in Denmark. BMC
613		Infect Dis. 2022;22:143. Available from: https://doi.org/10.1186/s12879-022-07102-1
614	40.	Hansen CB, Dvoncova K, Pérez-Alós L, Fogh K, Madsen JR, Garred CH, et al. SARS-CoV-
615		2 antibody dynamics over time and risk factors associated with infection and long
616		COVID-19 symptoms in large working environments. J Intern Med. 2023;293(6):763–
617		81.
618	41.	Lu P, Kong D, Shelley M. Risk perception, preventive behavior, and medical care
619		avoidance among American older adults during the COVID-19 pandemic. J Aging
620		Health. 2021;33(7–8):577–84.
621	42.	Montaño-Castellón I, Lins-Kusterer L, Luz E, Pedroso C, Paz M, Brites C. SARS-CoV-2
622		incidence, signs and symptoms and main risk factors for COVID-19 infection in health
623		care workers: A hospital-wide survey in Salvador, Brazil. Brazilian J Infect Dis.
624		2022;26(4):102387.
625	43.	Shamsundara M, Jayalakshmi L. Anosmia—An effect of COVID-19 infection-review.
626		Indian J Otolaryngol Head Neck Surg. 2023;75:S815–21. Available from:
627		https://doi.org/10.1007/s12070-022-03401-w
628	44.	Mehraeen E, Behnezhad F, Salehi MA, Noori T, Harandi H, SeyedAlinaghi SA. Olfactory
629		and gustatory dysfunctions due to the coronavirus disease (COVID-19): a review of
630		current evidence. Eur Arch Oto-Rhino-Laryngology. 2021;278(2):307–12. Available
631		from: https://doi.org/10.1007/s00405-020-06120-6
632	45.	Schenten D, Bhattacharya D. Immunology of SARS-CoV-2 infections and vaccines. Adv

Page **35** of **38**

633 Immunol. 2021;151:49–97. 634 46. Tian Y, Carpp LN, Miller HE, Zager M, Newell EW, Gottardo R. Singular insights into the immunology of SARS-CoV-2 infection. Nat Biotechnol. 2022;40(1):30-41. 635 47. DiPiazza AT, Graham BS, Ruckwardt TJ. T cell immunity to SARS-CoV-2 following 636 natural infection and vaccination. Biochem Biophys Res Commun. 2021;538:211–7. 637 48. Forchette L, Sebastian W, Liu T. A comprehensive review of COVID-19 virology, 638 vaccines, variants, and therapeutics. Curr Med Sci. 2021;41(6):1037–51. 639 640 49. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 641 2021;184:861-80. 642 50. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China Chuan. Clin Infect Dis. 2020;71(15):762-8. 643 644 51. Singh M, Barrera Adame O, Nickas M, Robison J, Khatchadourian C, Venketaraman V. Type 2 diabetes contributes to altered adaptive immune responses and vascular 645 inflammation in patients with SARS-CoV-2 infection. Front Immunol. 2022;13:833355. 646 52. Moguem Soubgui AF, Kojom Foko LP, Embolo Enyegue EL, Ndeme Mboussi WS, Mbebi 647 648 Enone JP, Ntatou Lemouchele I, et al. Confounding role of comorbidities and COVID-649 19 vaccination uptake in clinical utility of hematological biomarkers in Cameroonian patients infected with SARS–CoV–2. IJID. 2023; Ahead of Print. 650 53. Parthasarathi A, Basavaraja CK, Arunachala S, Chandran S, Venkataraman H, Satheesh 651 652 A, et al. Comorbidities influence the predictive power of hematological markers for mortality in hospitalized COVID-19 patients. Adv Respir Med. 2022;90(1):49-59. 653

654	54.	Centers for Disease Control and Prevention. People who are at higher risk for severe
655		illness CDC. Centers Dis Control Prev. 2020;68:703–10. Available from:
656		https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-
657		higher-risk.html
658	55.	Moguem Soubgui AF, Embolo Enyegue EL, Kojom Foko LP, Ndeme Mboussi WS,
659		Deutou Hogoue G, Mbougang SP, et al. Epidemiological situation of SARS-CoV-2
660		infection in Douala, the most populated and highly heterogeneous town of Cameroon:
661		a post-vaccination update. Acta Trop. 2023;241:106864. Available from:
662		https://doi.org/10.1016/j.actatropica.2023.106864
663	56.	Ebongue MSN, Lemogoum D, Endale-Mangamba LM, Barche B, Eyoum C, Simo Yomi
664		SH, et al. Factors predicting in-hospital all-cause mortality in COVID 19 patients at the
665		Laquintinie Hospital Douala, Cameroon. Travel Med Infect Dis. 2022;47:102292.
666		Available from: https://doi.org/10.1016/j.tmaid.2022
667	57.	Mercado-Reyes MM, Daza M, Pacheco A, Meneses-Gil MX, Galindo M, Catama J, et al.
668		Seroprevalence of SARS-CoV-2 antibodies in children and adolescents: Results from a
669		population-based survey in 10 Colombian cities. Glob Pediatr Heal. 2022;9:1–16.
670	58.	Talaei M, Faustini S, Holt H, Jolliffe DA, Vivaldi G, Greenig M, et al. Determinants of
671		pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal
672		study (COVIDENCE UK). BMC Med. 2022;20:87. Available from:
673		https://doi.org/10.1186/s12916-022-02286-4

- 674 59. Rodríguez MF, Porras-Villamil JF, Martin L V., Rivera JE, Mantilla YC, Olivera MJ.
- 675 Seroprevalence of IgM and IgG anti-SARS-COV-2 and associated factors among
- agricultural workers in Colombia. New Microbes New Infect. 2022;48:101026.

	Available from: https://doi.org/10.1016/j.nmni.2022.101026
60.	Colson P, Delerce J, Burel E, Dahan J, Jouffret A, Fenollar F, et al. Emergence in
	southern France of a new SARS-CoV-2 variant harbouring both N501Y and E484K
	substitutions in the spike protein. Arch Virol. 2022;167(4):1185–90. Available from:
	https://doi.org/10.1007/s00705-022-05385-y
61.	Chouikha A, Lagare A, Ghedira K, Diallo A, Njouom R, Sankhe S, et al. SARS-CoV-2
	lineage A.27: New data from African countries and dynamics in the context of the
	COVID-19 pandemic. Viruses. 2022;14(5):1007.
62.	Njouom R, Sadeuh-mba SA, Tchatchueng J, Dia N, Tagnouokam Ngoupo PA, Boum Y,
	et al. Coding-complete genome sequence and phylogenetic relatedness of a SARS-
	CoV-2 strain detected in March 2020 in Cameroon. Microbiol Resour Announc.
	2020;3:e00093-21.
	60.

697 Supporting information

- 698 S1 Fig. Ethical clearance of the study.
- 699 S2 Fig. Testing SARS-CoV-2 immune response parameters (IgM, IgG, CD4+, IFN-γ and IL-6)
- 700 and age for Gaussian distribution.
- 701 S3 Table. SARS-CoV-2 seroprevalence profile by health facilities.
- 702 **S4 Table. SARS-CoV-2 seroprevalence profile by clinical symptoms.**
- 703 **S5 Table. Clinical value of symptoms for prognostic of IgG seropositivity.**
- 704 S6 Table. Association between immune response and patients' characteristics among
- 705 COVID-19 unvaccinated patients.
- 706 **S7 Table. Details of multivariate logistic regression analysis of the presence of anti-SARS-**
- 707 CoV-2 IgM or IgG antibodies.



Fig 1



Fig 2



IgG (+)



Study sites





Fig 4





Fig 5

Gender





p=0.98

p=0.001*

60- = Age <60 yrs

60+ = Age ≥ 60 yrs

60- 60+ 60- 60+ 60- 60+ 60- 60+

8

IgM+

(21)

6

IgG-

(86) (51)

IgG+

 $\rho = 0.23$

p=0.11

Ő.

(12) (18) (89)

IgM-



AS = Asymptomatic

S = Symptomatic

AS S AS S

AS = Asymptomatic

6

30

IgM+

(46)

p=0.01*

p=0.16

p=0.11

AS S

IgG+

Ē 6 (38)

IgG-

p=0.93



O- = No obesity

O+ = Obesity

5

IgM+

6

IgG-

66

p= 0.006*

p=0.05

p=0.25

1000

800

600

400

200

Ô,

<u>-</u> 53) (61) 6

IgM-

(cells/µL)

CD4+

Diabetes











1000

800

600

400

200

ō

AS S

IgM-

(12)

Ē

CD4+ (cells/µL)







D- = No diabetes

H- = No hypertension H+ = Hypertension





Fig 6



IgM-

IgM+

IgG-

IgG+









